AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerJung‐Yun Lee, Lingying Wu, Guangwen Yuan et al.|Gynecologic Oncology|2025Cited by 7